Abstract | OBJECTIVE:
Hypertension affects 50-90% of kidney transplant recipients and is associated with cardiovascular disease and graft loss. We aimed to evaluate the comparative benefits and harms of blood pressure lowering agents in people with a functioning kidney transplant. METHODS: We conducted a systematic review with network meta-analysis of randomized controlled trials (RCTs). We searched MEDLINE, Embase, and CENTRAL through to October 2023. RCTs evaluating blood pressure lowering agents administered for at least 2 weeks in people with a functioning kidney transplant with and without preexisting hypertension were eligible. Two reviewers independently extracted data. The primary outcome was graft loss. Treatment effects were estimated using random effects network meta-analysis, with treatment effects expressed as an odds ratio (OR) for binary outcomes and mean difference (MD) for continuous outcomes together with their 95% confidence interval (CI). Confidence in the evidence was assessed using GRADE for network meta-analysis. RESULTS: Ninety-four studies (7547 adults) were included. Two studies were conducted in children. No blood pressure-lowering agent reduced the risk of graft loss, withdrawal because of adverse events, death, cardiovascular or kidney outcomes compared with placebo/other drug class. Angiotensin-converting enzyme inhibitors and angiotensin receptor blocker therapy may incur greater odds of hyperkalemia compared with calcium channel blockers [odds ratio (OR) 5.48, 95% confidence interval (CI) 2.47-12.16; and OR 8.67, 95% CI 2.65-28.36; low certainty evidence, respectively). CONCLUSION: The evidentiary basis for the comparative benefits and safety of blood pressure lowering agents in people with a functioning kidney transplant is limited to guide treatment decision-making.
|
Authors | Patrizia Natale, Suetonia C Palmer, Allison Jaure, Valeria Saglimbene, Andrea Iannone, Amanda Sluiter, Jonathan Craig, Giovanni F M Strippoli |
Journal | Journal of hypertension
(J Hypertens)
Vol. 42
Issue 5
Pg. 848-855
(May 01 2024)
ISSN: 1473-5598 [Electronic] Netherlands |
PMID | 38230619
(Publication Type: Meta-Analysis, Systematic Review, Journal Article)
|
Copyright | Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved. |
Chemical References |
- Angiotensin-Converting Enzyme Inhibitors
|
Topics |
- Child
- Adult
- Humans
- Blood Pressure
- Kidney Transplantation
(adverse effects)
- Network Meta-Analysis
- Hypertension
(drug therapy)
- Angiotensin-Converting Enzyme Inhibitors
(therapeutic use)
|